title: Degrees of dysplasia based on viral typing in patients with cidofovir use and recurrent respiratory papillomatosis.
abstract: OBJECTIVE
  To evaluate the degree of dysplasia following cidofovir injections while documenting human papillomavirus (HPV) type in patients with recurrent respiratory papillomatosis (RRP).
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  Demographic data, operative reports, and pathology results were reviewed from 25 patients with RRP who had had cidofovir injections. All patients included had adult onset RRP, no history of immunosuppression, well-controlled laryngopharyngeal reflux, and no current smoking history. Eight patients were excluded because they did not meet the inclusion criteria.
  
  
  RESULTS
  Seventeen patients had adequate data for analysis and 40 subsites were identified with sufficient data for analysis. Patients negative for both low and high risk did not have progressive dysplasia at the conclusion of the study. Of the patients with positive viral typing, 70% had progressive disease at the conclusion of the study. No patients progressed to carcinoma or carcinoma in situ. The average pre- and post-treatment dysplasia scores were analyzed using a Student paired t test. There was no difference in mean dysplasia score, indicating that there was no increased risk of dysplasia following cidofovir treatment.
  
  
  CONCLUSIONS
  To our knowledge, this is the first study looking at the degree of dysplasia while documenting HPV types in RRP. Our study suggests that HPV type appears to be relevant in the disease progression of RRP and that cidofovir does not increase the risk of dysplasia.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Drexel University, College of Medicine, Philadelphia, Pennsylvania. Electronic address: jeaglinmoore@phillyent.com.
authors.forename: Jaime Eaglin
authors.initials: JE
authors.lastname: Moore
authors.forename: Anna
authors.initials: A
authors.lastname: Garcia
authors.forename: Samudra
authors.initials: S
authors.lastname: Sanyal
authors.forename: Stefanie
authors.initials: S
authors.lastname: Saunders
authors.forename: Joel E
authors.initials: JE
authors.lastname: Portnoy
authors.forename: Amanda
authors.initials: A
authors.lastname: Hu
authors.forename: Robert T
authors.initials: RT
authors.lastname: Sataloff
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D000077404:Cidofovir; D003596:Cytosine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects*; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000821:virology*; D011230:Precancerous Conditions / Q000139:chemically induced / Q000821:virology*; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000821:virology*; D012142:Respiratory Tract Neoplasms / Q000139:chemically induced / Q000821:virology*; D012189:Retrospective Studies
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir
keywords: Cidofovir; Dysplasia; Human papillomavirus; Recurrent respiratory papillomas